default author photo

David Knorr

Memorial Sloan Kettering Cancer Center - Department of Medicine

SCHOLARLY PAPERS

2

DOWNLOADS

58

TOTAL CITATIONS

0

Scholarly Papers (2)

Actions:
Email selected abstracts
1.

FcyRIIB Is a Novel Immune Checkpoint in the Tumor Microenvironment Limiting Activity of Treg-Targeting Antibodies

Number of pages: 30 Posted: 20 Jan 2023
David Knorr, Rom S. Leidner, Shawn Jensen, Ryan Meng, Andrew Jones, Carmen Ballesteros-Merino, R. Bryan Bell, Maria Baez, David Sprott, Carlo B. Bifulco, Brian Penning, Rony Dahan, Bernard Fox and Jeffrey Ravetch
Memorial Sloan Kettering Cancer Center - Department of Medicine, Providence Cancer Center - Earle A. Chiles Research Institute, Providence Cancer Center - Earle A. Chiles Research Institute, Providence Cancer Center - Earle A. Chiles Research Institute, Rockefeller University - Laboratory of Molecular Genetics and Immunology, Bristol-Myers Squibb, Providence Cancer Center - Earle A. Chiles Research Institute, Rockefeller University - Laboratory of Molecular Genetics and Immunology, Providence Cancer Center - Earle A. Chiles Research Institute, Providence Cancer Center - Earle A. Chiles Research Institute, Providence Cancer Center - Earle A. Chiles Research Institute, Weizmann Institute of Science - Department of Immunology, Providence Cancer Center - Earle A. Chiles Research Institute and Rockefeller University - Laboratory of Molecular Genetics and Immunology
Downloads 30 (1,345,526)

Abstract:

Loading...

Fc-engineered antibodies, antibody therapy, cancer immunology, immunotherapy, T regulatory cell

2.

Spatially Organized Dendritic Cell–t Cell Interactions Are Associated With Response to Cd40 Agonism in Non-muscle Invasive Bladder Cancer

Number of pages: 47 Posted: 14 Apr 2026
Juan Carlos Osorio, Lucas Blanchard, Ning Yao, Syed M. Alam, Ali Ghasemzadeh, Karissa Whiting, Venkatraman E Seshan, Andrew Mijacika, Carlo Sevilla, Juan Angulo-Lozano, Ved P. Sharma, Morgan Tomberlin, Melissa McCarter, Jessica Pfau, Jeffrey L. Wong, David Knorr, Timothy F. Donahue, Robert Smith, Eugene J. Pietzak, Benjamin D. Greenbaum, Hikmat A. Al-Ahmadie, Jonathan E. Rosenberg, Jeffrey Ravetch and Bernard H. Bochner
Rockefeller University - Laboratory of Molecular Genetics and Immunology, Rockefeller University - Laboratory of Molecular Genetics and Immunology, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center - Department of Epidemiology and Biostatistics, Rockefeller University - Laboratory of Molecular Genetics and Immunology, Memorial Sloan Kettering Cancer Center, affiliation not provided to SSRN, Rockefeller University - Laboratory of Molecular Genetics and Immunology, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center - Department of Medicine, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, Rockefeller University - Laboratory of Molecular Genetics and Immunology and Memorial Sloan Kettering Cancer Center
Downloads 28 (1,481,165)

Abstract:

Loading...

CD40, Fc Receptor, non-muscle invasive bladder cancer, immune triads, tertiary lymphoid structures, dendritic cells, BCG, cancer immunotherapy, antibody, clinical trial